Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has applied to the ASX for quotation of 1,736,111 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The additional shares, issued on 7 January 2026, modestly expand Imugene’s quoted capital base and reflect ongoing utilisation of equity-linked incentives or funding structures, with implications for shareholder dilution but also providing incremental capital support for the company’s biotechnology development activities.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited, listed on the ASX under the code IMU, operates in the biotechnology sector, focusing on the development and commercialisation of immuno-oncology therapies. The company targets cancer treatment markets, seeking to advance novel immunotherapies through clinical development and strategic capital market activities to support its research pipeline.
Average Trading Volume: 1,397,104
Technical Sentiment Signal: Sell
Current Market Cap: A$109.7M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.